# Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

> **NCT06138496** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 39 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Cadonilimab Combined With Lenvatinib

## Key facts

- **NCT ID:** NCT06138496
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-01
- **Primary completion:** 2024-12-09
- **Final completion:** 2025-12-31
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06138496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06138496, "Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06138496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*